INFLUENCIA DEL RITMO LUZ-OSCURIDAD EN LOS BIOMARCADORES CIRCULANTES RELACIONADOS CON LA ATEROTROMBOSIS

INFLUENCIA DEL RITMO LUZ-OSCURIDAD EN LOS BIOMARCADORES CIRCULANTES RELACIONADOS CON LA ATEROTROMBOSIS

(especial para SIIC © Derechos reservados)
Las enfermedades cardiovasculares son la primera causa de muerte en el mundo occidental. El objetivo de esta revisión es conocer la asociación potencial entre la inflamación cardiovascular y el ritmo circadiano, obteniendo un mayor conocimiento en la fisiopatología de los diferentes biomarcadores, mejorando así su uso en la enfermedad cardiovascular.
dominguezrodriguez9_103012.jpg Autor:
Alberto Dominguez-rodriguez
Columnista Experto de SIIC

Institución:
Hospital Universitario de Canarias. Servicio de Cardiología


Artículos publicados por Alberto Dominguez-rodriguez
Coautor
Pedro Abreu-Gonzalez* 
Universidad de La Laguna, La Laguna, España*
Recepción del artículo
18 de Julio, 2012
Aprobación
24 de Septiembre, 2012
Primera edición
12 de Noviembre, 2012
Segunda edición, ampliada y corregida
7 de Junio, 2021

Resumen
El sustrato inflamatorio involucrado en la aterotrombosis es extremadamente complejo, con un gran número de factores implicados tanto en su activación como en su modulación. Las variaciones de las funciones inflamatorias en el transcurso de las 24 horas del día permitirían identificar los momentos del día o de la noche en que picos de actividad inflamatoria pudieran asociarse con una mayor incidencia de eventos cardiovasculares. A la hora de seleccionar un biomarcador es necesario estandarizar los métodos de determinación, establecer puntos de corte que permitan definir si realmente hay valores que separan a las poblaciones con diferentes riesgos de una manera clara, y establecer con qué frecuencia y en qué momento del día se deberían extraer las muestras de sangre. Teniendo en cuenta la asociación potencial entre la inflamación y el ritmo circadiano, un mejor conocimiento sobre la cinética de los biomarcadores inflamatorios podría conducir a mejorar su uso en la enfermedad cardiovascular. El objetivo de esta revisión es conocer la existencia de una variabilidad diurna de determinadas moléculas que intervienen en la fisiopatología de la aterotrombosis coronaria, con el fin de tenerlas en cuenta a la hora de diseñar futuros estudios que involucren a determinados biomarcadores.

Palabras clave
biomarcadores, aterotrombosis, variación diurna, ritmo luz-oscuridad, síndrome coronario agudo


Artículo completo

(castellano)
Extensión:  +/-7.19 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
The inflammatory substrate involved in atherothrombosis is extremely complex and has a number of factors involved in both activation and modulation. Variations in the inflammatory functions over the 24 hours of the day could enable professionals to identify times of day or night at which the inflammatory activity peaks could be associated with a higher incidence of cardiovascular events. When selecting a biomarker it is necessary to standardise decision-making methods and establish cut-off points that would reveal whether there are really values that can clearly separate populations with different risks, and decide how often and at what time of day blood samples should be extracted. Given the potential association between inflammation and circadian rhythm, a better understanding of the kinetics of inflammatory biomarkers could lead to better use in cardiovascular disease. The aim of this review is to determine the existence of a diurnal variability of certain molecules involved in the pathophysiology of coronary atherothrombosis, in order to take them into account when designing future studies involving specific biomarkers.

Key words
biomarkers, atherothrombosis, diurnal variation, rhythm light-dark, acute coronary syndrome


Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Cardiología, Diagnóstico por Laboratorio
Relacionadas: Bioquímica, Cuidados Intensivos, Endocrinología y Metabolismo, Medicina Interna



Comprar este artículo
Extensión: 7.19 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Alberto Domínguez Rodríguez, Universidad de la Laguna., E-38320, Hospital Universitario de Canarias. Servicio de Cardiología. Ofra s/n La Cuesta., Tenerife, España
Bibliografía del artículo
1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 349:1269-76, 1997.
2. Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol 17:1859-67, 1997.
3. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 326:242-50, 1992.
4. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 326:310-8, 1992.
5. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 109(Suppl 1):IV6-19, 2004.
6. Tanaka A, Kawarabayashi T, Fukuda D y col. Circadian variation of plaque rupture in acute myocardial infarction. Am J Cardiol 93:1-5, 2004.
7. Domínguez Rodríguez A, García González MJ, Abreu González P, Ferrer Hita J. [Circadian rhythm in acute coronary syndrome]. Med Clin (Barc) 124:595, 2005.
8. Abo T, Kawate T, Itoh K, Kumagai K. Studies on the bioperiodicity of the immune response. I. Circadian rhythms of human T, B, and K cell traffic in the peripheral blood. J Immunol 126:1360-3, 1981.
9. Dominguez-Rodriguez A, Garcia-Gonzalez M, Abreu-Gonzalez P. Link between arterial inflammation and circadian rhythm: the oversight aspect in the year 2004. J Am Coll Cardiol 47:688-9, 2006.
10. Martín-Ventura JL, Blanco-Colio LM, Tuñón J y col. Biomarkers in cardiovascular medicine. Rev Esp Cardiol 62:677-88, 2009.
11. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113:2335-62, 2006.
12. Domínguez-Rodríguez A, Abreu-González P. [Inflammatory biomarkers in the acute coronary syndrome]. Med Clin (Barc) 136:461-2, 2011.
13. Dominguez-Rodriguez A, Abreu-Gonzalez P, Kaski JC. Inflammatory systemic biomarkers in setting acute coronary syndromes-effects of the diurnal variation. Curr Drug Targets 10:1001-8, 2009.
14. Adams DH, Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet 343:831-6, 1994.
15. Davies MJ, Gordon JL, Gearing AJ y col. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 171:223-9, 1993.
16. Maple C, Kirk G, McLaren M, Veale D, Belch JJ. A circadian variation exists for soluble levels of intercellular adhesion molecule-1 and E-selectin in healthy volunteers. Clin Sci (Lond) 94:537-40, 1998.
17. Osmancik P, Kvasnicka J, Widimsky P, Tarnok A. Diurnal variation of soluble E- and P-selectin, and intercellular adhesion molecule-1 in patients with and without coronary artery disease. Cardiology 102:194-9, 2004.
18. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Samimi-Fard S, Kaski JC, Reiter RJ. Light/dark patterns of soluble vascular cell adhesion molecule-1 in relation to melatonin in patients with ST-segment elevation myocardial infarction. J Pineal Res 44:65-9, 2008.
19. Domínguez Rodríguez A, Abreu González P. Diurnal variations in biomarkers used in cardiovascular medicine: clinical significance. Rev Esp Cardiol 62:1340-1, 2009.
20. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-9, 1997.
21. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557-65, 2002.
22. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731-3, 1998.
23. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836-43, 2000.
24. Ballantyne CM, Hoogeveen RC, Bang H y col. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109:837-42, 2004.
25. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol 35:1535-42, 2000.
26. Mueller C, Buettner HJ, Hodgson JM y col. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 105:1412-5, 2002.
27. Zebrack JS, Anderson JL, Maycock CA, Horne BD, Bair TL, Muhlestein JB; Intermountain Heart Collaborative (IHC) Study Group. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol 89:145-9, 2002.
28. Dominguez-Rodriguez A, Garcia-Gonzalez M, Abreu-Gonzalez P, Ferrer J, Kaski JC. Relation of nocturnal melatonin levels to C-reactive protein concentration in patients with ST-segment elevation myocardial infarction. Am J Cardiol 97:10-2, 2006.
29. Rudnicka AR, Rumley A, Lowe GD, Strachan DP. Diurnal, seasonal, and blood-processing patterns in levels of circulating fibrinogen, fibrin D-dimer, C-reactive protein, tissue plasminogen activator, and von Willebrand factor in a 45-year-old population. Circulation 115:996-1003, 2007.
30. Koc M, Karaarslan O, Abali G, Batur MK. Variation in high-sensitivity C-reactive protein levels over 24 hours in patients with stable coronary artery disease. Tex Heart Inst J 37:42-8, 2010.
31. Dominguez-Rodriguez A, Abreu-Gonzalez P, Juarez-Prera RA y col. Usefulness of serum neopterin levels in acute decompensated heart failure to predict renal dysfunction. Biomarkers. 2011 Dec 22. [Artículo en prensa].
32. Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P, Laynez-Cerdeña I, Kaski JC. Neopterin predicts left ventricular remodeling in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Atherosclerosis 211:574-8, 2010.
33. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez M. Usefulness of neopterin levels and left ventricular function for risk assessment in survivors of acute myocardial infarction. Int J Cardiol 111:318-20, 2006.
34. Kaski JC, Consuegra-Sánchez L, Fernández-Berges DJ y col. Elevated serum neopterin levels and adverse cardiac events at 6 months follow-up in Mediterranean patients with non-STsegment elevation acute coronary syndrome. Atherosclerosis 201:176-83, 2008.
35. Avanzas P, Arroyo-Espliguero R, Cosín-Sales J, Quiles J, Zouridakis E, Kaski JC. Prognostic value of neopterin levels in treated patients with hypertension and chest pain but without obstructive coronary artery disease. Am J Cardiol 93:627-9, 2004.
36. Avanzas P, Arroyo-Espliguero R, Quiles J, Roy D, Kaski JC. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur Heart J 26:457-63, 2005.
37. Avanzas P, Arroyo-Espliguero R, Cosín-Sales J y col. Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes. Heart 90:847-52, 2004.
38. Avanzas P, Domínguez-Rodríguez A, Arroyo-Espliguero R, Kaski JC. Neopterin and coronary artery disease. J Cardiol 54:344-5, 2009.
39. Avanzas P, Arroyo-Espliguero R, Kaski JC. Neopterin - marker of coronary artery disease activity or extension in patients with chronic stable angina? Int J Cardiol 144:74-5, 2010.
40. Avanzas P, Arroyo-Espliguero R, Garcia-Moll X, Kaski JC. Inflammatory biomarkers of coronary atheromatous plaque vulnerability. Panminerva Med 47:81-91, 2005.
41. Auzéby A, Bogdan A, Krosi Z, Touitou Y. Time-dependence of urinary neopterin, a marker of cellular immune activity. Clin Chem 34:1866-7, 1988.
42. García González MJ, Domínguez Rodríguez A, Abreu González P. Diurnal variations in serum neopterin levels are associated with the pineal hormone melatonin circadian rhythm in healthy human subjects. J Pineal Res 40:288-9, 2006.
43. Levi FA, Canon C, Touitou Y, Sulon J, Mechkouri M, Ponsart ED, et al. Circadian rhythms in circulating T lymphocyte subtypes and plasma testosterone, total and free cortisol in five healthy men. Clin Exp Immunol 71:329-35, 1988.
44. García-González MJ, Domínguez-Rodríguez A, Abreu-González P. Light-dark variations in neopterin serum levels in patients with ST-segment elevation acute coronary syndrome undergoing primary angioplasty. Rev Esp Cardiol 61:1280-6, 2008.
45. Schieffer B, Schieffer E, Hilfiker-Kleiner D y col. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 101:1372-8, 2000.
46. Ikeda U, Ito T, Shimada K. Interleukin-6 and acute coronary syndrome. Clin Cardiol 24:701-4, 2001.
47. Biasucci LM, Liuzzo G, Fantuzzi G y col. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 99:2079-84, 1999.
48. Koukkunen H, Penttilä K, Kemppainen A y col. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann Med 33:37-47, 2001.
49. Domínguez Rodríguez A, Abreu González P, García MJ, de la Rosa A, Vargas M, Marrero F. [Circadian variations in proinflammatory cytokine concentrations in acute myocardial infarction]. Rev Esp Cardiol 56:555-60, 2003.
50. Dominguez-Rodriguez A, Abreu-Gonzalez P. Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction. Clin Cardiol 32:288, 2009.
51. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia M y col. Light/dark patterns of interleukin-6 in relation to the pineal hormone melatonin in patients with acute myocardial infarction. Cytokine 26:89-93, 2004.
52. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827-39, 2003.
53. Lu L, Gunja-Smith Z, Woessner JF y col. Matrix metalloproteinases and collagen ultrastructure in moderate myocardial ischemia and reperfusion in vivo. Am J Physiol Heart Circ Physiol 279:H601-9, 2000.
54. Lindsey M, Wedin K, Brown MD y col. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 103:2181-7, 2001.
55. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 141:211-7, 2001.
56. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 59:812-23, 2003.
57. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC. High serum matrix metalloproteinase-9 level predict increased risk of in-hospital cardiac events in patients with type 2 diabetes and ST segment elevation myocardial infarction. Atherosclerosis 196:365-71, 2008.
58. Ferroni P, Basili S, Martini F y col. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Invest Med 51:295-300, 2003.
59. Tayebjee MH, Lip GY, Blann AD, MacFadyen RJ. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb Res 115:205-10, 2005.
60. Dominguez Rodriguez A, Abreu Gonzalez P, Garcia Gonzalez MJ, Reiter RJ. Relation of nocturnal melatonin levels to serum matrix metalloproteinase-9 concentrations in patients with myocardial infarction. Thromb Res 120:361-6, 2007.
61. Domínguez-Rodríguez A, Kaski JC, Abreu-González P, García-González MJ. [The kinetics of metalloproteinase-9: the significance of the light-dark cycle in metalloproteinase-9 in acute coronary syndrome]. Rev Esp Cardiol 61:327, 2008.
62. Dominguez-Rodriguez A, Abreu-Gonzalez P. Current role of myeloperoxidase in routine clinical practice. Expert Rev Cardiovasc Ther 9:223-30, 2011.
63. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 158:879-91, 2001.
64. Zhang R, Brennan ML, Fu X y col. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286:2136-42, 2001.
65. Samimi-Fard S, Dominguez-Rodriguez A, Abreu-Gonzalez P y col. Role of myeloperoxidase as predictor of systemic inflammatory response syndrome in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention. Am J Cardiol 104:634-7, 2009.
66. Dominguez-Rodriguez A, Samimi-Fard S, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC. Prognostic value of admission myeloperoxidase levels in patients with ST-segment elevation myocardial infarction and cardiogenic shock. Am J Cardiol 101:1537-40, 2008.
67. Dominguez-Rodriguez A, Abreu-Gonzalez P, Kaski JC. Diurnal variation of circulating myeloperoxidase levels in patients with ST-segment elevation myocardial infarction. Int J Cardiol 144:407-9, 2010.
68. Dominguez-Rodriguez A, Abreu-Gonzalez P. Myeloperoxidase in the acute coronary syndrome: equal concentrations at any time of day? Int J Cardiol 150:206-7, 2011.
69. Schönbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 89:1092-103, 2001.
70. Furman MI, Barnard MR, Krueger LA y col. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 38:1002-6, 2001.
71. André P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106:896-9, 2002.
72. Garlichs CD, Eskafi S, Raaz D y col. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 86:649-55, 2001.
73. Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P y col. Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention--effects on soluble CD40 ligand concentrations. Atherosclerosis 206:523-7, 2009.
74. Bremner WF, Sothern RB, Kanabrocki EL y col. Relation between circadian patterns in levels of circulating lipoprotein(a), fibrinogen, platelets, and related lipid variables in men. Am Heart J 139:164-73, 2000.
75. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC. Diurnal variation of soluble CD40 ligand in patients with acute coronary syndrome. Soluble CD40 ligand and diurnal variation. Thromb Res 123:617-21, 2009.
76. Dominguez-Rodríguez A, Abreu-Gonzalez P. Light-dark patterns of soluble CD40 ligand: clinical implications. Am Heart J 157:e3, 2009.
77. Dominguez-Rodriguez A, Abreu-Gonzalez P, Sanchez-Sanchez JJ, Kaski JC, Reiter RJ. Melatonin and circadian biology in human cardiovascular disease. J Pineal Res 49:14-22, 2010.

 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618